$776 Million is the total value of Vivo Capital, LLC's 40 reported holdings in Q2 2018. The portfolio turnover from Q1 2018 to Q2 2018 was 0.0% .
Value | Shares | ↓ Weighting | ||||||
---|---|---|---|---|---|---|---|---|
ASND | Ascendis Pharmaadr | $144,138,000 | +1.7% | 2,166,832 | 0.0% | 18.57% | -7.5% | |
BHVN | Biohaven Pharmaceutical Holding Company Ltd | $80,998,000 | +53.4% | 2,049,545 | 0.0% | 10.44% | +39.6% | |
CDXS | Codexis, Inc. | $43,989,000 | +30.9% | 3,054,825 | 0.0% | 5.67% | +19.1% | |
ACRS | Aclaris Therapeutics | $32,895,000 | +14.0% | 1,647,214 | 0.0% | 4.24% | +3.7% | |
MNLO | Menlo Therapeutics | $32,571,000 | -78.4% | 4,011,236 | 0.0% | 4.20% | -80.3% | |
ARWR | Arrowhead Pharmaceuticals In | $25,840,000 | +88.6% | 1,900,000 | 0.0% | 3.33% | +71.6% | |
EIGR | Eiger BioPharmaceuticals | $21,853,000 | +23.9% | 1,791,257 | 0.0% | 2.82% | +12.7% | |
AMRS | Amyris, Inc. | $18,063,000 | -4.5% | 2,826,711 | 0.0% | 2.33% | -13.1% | |
KALA | Kala Pharmaceuticals, Inc. | $14,321,000 | -13.3% | 1,043,020 | 0.0% | 1.84% | -21.1% | |
Nabriva Therapeutics Plc | $14,178,000 | -30.8% | 4,074,190 | 0.0% | 1.83% | -37.1% | ||
SBBP | Strongbridge Biopharma plc | $11,509,000 | -32.2% | 1,918,132 | 0.0% | 1.48% | -38.3% | |
SRRA | Sierra Oncology, Inc | $7,217,000 | +43.0% | 2,438,270 | 0.0% | 0.93% | +30.1% | |
GNCA | Genocea Biosciences Inc(NMS) | $7,000,000 | -18.5% | 8,180,000 | 0.0% | 0.90% | -25.9% | |
AUPH | Aurinia Pharmaceuticals Inc. | $6,831,000 | +8.5% | 1,213,290 | 0.0% | 0.88% | -1.3% | |
ZGNX | Zogenix, Inc. | $4,641,000 | +10.4% | 105,000 | 0.0% | 0.60% | +0.3% | |
FOMX | Foamix Pharmaceuticals Ltd. | $4,284,000 | -2.3% | 855,000 | 0.0% | 0.55% | -11.1% | |
BPMX | BioPharmX Corporation | $3,561,000 | -4.4% | 16,128,515 | 0.0% | 0.46% | -13.1% | |
VRNA | Verona Pharma Plcads | $2,792,000 | -90.6% | 1,492,951 | 0.0% | 0.36% | -91.5% | |
TRVN | Trevena, Inc. | $2,488,000 | -12.2% | 1,728,000 | 0.0% | 0.32% | -20.0% | |
KALV | KalVista Pharmaceuticals, Inc. | $2,439,000 | -14.3% | 300,325 | 0.0% | 0.31% | -22.1% | |
AGRX | Agile Therapeutics, Inc. | $742,000 | -80.9% | 1,513,975 | 0.0% | 0.10% | -82.6% | |
AKTX | Akari Therapeutics Plcadr | $674,000 | +7.2% | 345,850 | 0.0% | 0.09% | -2.2% | |
SNSS | Sunesis Pharmaceuticals, Inc. | $414,000 | -22.2% | 195,474 | 0.0% | 0.05% | -29.3% | |
SLNOW | Soleno Therapeutics, Inc.warrant | $79,000 | +243.5% | 188,772 | 0.0% | 0.01% | +233.3% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-08-10
Top long-term holdings
Name | Quarters owned | Latest quarter owned | Max weighting |
---|---|---|---|
ACLARIS THERAPEUTICS INC | 29 | Q3 2023 | 33.5% |
CODEXIS INC | 29 | Q3 2023 | 8.0% |
ASCENDIS PHARMA A/S | 25 | Q3 2022 | 24.0% |
KALVISTA PHARMACEUTICALS INC | 25 | Q3 2023 | 3.9% |
Verona Pharma PLC ADR | 24 | Q3 2023 | 7.6% |
AMYRIS INC | 23 | Q3 2023 | 8.8% |
EIGER BIOPHARMACEUTICALS INC | 23 | Q1 2022 | 8.7% |
Zai Lab Ltd ADR | 22 | Q3 2023 | 1.8% |
Arrowhead Pharmaceuticals Inc | 21 | Q3 2023 | 6.9% |
HOMOLOGY MEDICINES INC | 21 | Q3 2023 | 3.7% |
View Vivo Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
Filed | Shares | Percentage | |
---|---|---|---|
SINOVAC BIOTECH LTDSold out | August 27, 2018 | 0 | 0.0% |
View Vivo Capital, LLC's complete significant-ownership history.
Latest filings
Type | Filed |
---|---|
13F-HR | 2024-04-22 |
13F-HR | 2024-02-07 |
13F-HR | 2023-11-08 |
13F-HR | 2023-08-14 |
13F-HR | 2023-05-15 |
13F-HR | 2023-02-13 |
13F-HR | 2022-11-14 |
13F-HR | 2022-08-15 |
13F-HR | 2022-05-13 |
13F-HR | 2022-02-11 |
View Vivo Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.